Insight Molecular Diagnostics (IMDX) Q2 2024 earnings summary

Executive summary

• Successfully launched GraftAssure, a research-use-only assay for early detection of graft organ damage, with initial deployments in major US and Southeast Asian transplant centers and positive feedback from beta customers.

• Achieved strategic partnership and investment from Bio-Rad, supporting commercialization, global launch, and growth, with Oncocyte leading in the US and Germany.

• Focused on maintaining a capital-light, high-margin business model, product development, and expanding strategic partnerships.

• Early adoption by research centers, including those studying pediatric transplant patients, highlights unmet needs being addressed and strong market enthusiasm.

• Ongoing shift from laboratory-developed tests to research use only (RUO) and kitted products, with a decentralized business model.

Financial highlights

• Q2 2024 revenue was $104,000, down 78% year-over-year, primarily from pharma services in Nashville.

• Net loss from continuing operations for Q2 2024 was $4.5 million, or $0.36 per share; non-GAAP loss from operations was $5.0 million.

• Operating expenses for Q2 2024 were $4.7 million, down from $8.6 million in Q2 2023, including $386,000 in stock-based compensation and $326,000 in depreciation/amortization.

• Cash, cash equivalents, and restricted cash at quarter-end totaled $11.0 million, up $3.7 million sequentially, including proceeds from April capital raise.

• April 2024 private placement raised $15.8 million gross ($9.9 million net), used in part to redeem all remaining Series A Preferred Stock.

Outlook and guidance

• Targeting more than 20 transplant centers running GraftAssure by end of 2025, with each center representing potential annual revenue of several hundred thousand to $2 million.

• Projected revenue path for a typical US center could reach $400,000 in quarterly run rate by 2028, assuming FDA clearance in late 2025 and MolDX reimbursement in early 2026.

• Ongoing Q-Sub process with FDA, aiming for feedback by end of 2024 and FDA IVD clearance in late 2025.

• Expects continued operating losses and negative cash flows for the foreseeable future, with plans to raise additional capital and maintain reduced spending levels.

• Modest revenue expected from RUO product until IVD product launch, with significant revenue inflection anticipated post-FDA approval.